CPRX (Catalyst Pharma) Gross Profit Rate

CPRX (Catalyst Pharma) - company brandmark

The growth foundation of Catalyst Pharmaceuticals (CPRX) is based on exclusive rights in the LEMS segment and high profitability. The gross margin history confirms this resilience, and 79.60 reflects the latest value of the metric. Effective commercialization of orphan therapies and a flawless reputation among physicians create a favorable environment for expanding the company's influence in neuromedicine.

catalystpharma.com (CPRX) Gross Profitability: for the period 07/04/2022 - 07/25/2026

Financial and market metric breakdowns for Catalyst Corp (CPRX)

- business market valuation indicators:
Core merchandise of Catalyst Pharmaceuticals Inc

Exclusive rights to drugs for rare neurological syndromes provide Catalyst Pharmaceuticals (CPRX) with high operational efficiency and significant excess liquidity. The relative gross margin trend digitizes the share of revenue minus direct production costs, allowing investors to assess the issuer's pricing power and the business's fundamental ability to generate profit, thereby minimizing the risk of overpaying for the asset.

Direct competitors

Return on Gross Profit Biogen Corp|Return on Gross Profit NBIX|Regencell Corp (RGC) - Return on Sales by Gross Profit|Gross Margin AXSM|Return on Gross Profit ACADIA Pharmaceuticals ACAD|Gross Margin XENE (Xenon Pharmaceuticals Inc.)|VKTX (Viking Therapeutics, Inc.) - Gross Profitability Margin|SUPN - Gross Profitability|Gross Profit Margin Denali Therapeutics|HRMY: Gross Margin|Biohaven - Gross Profit Rate|Return on Gross Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Return on Sales by Gross Profit|Return on Gross Profit PRAX (Praxis Medicines)|Anavex Corp - Gross Return on Sales|Gross Profitability CeriBell CBLL|Return on Sales by Gross Profit Prothena Biosciences (PRTA)|ALEC: Return on Gross Profit|ANNX - Gross Margin|Omeros Corp. (OMER) - Gross Profitability|Gross Profit Margin Neurogene Inc. (NGNE)|Return on Gross Profit ACIU|Gross Profitability VYGR|Gross Profitability Neumora (NMRA)|SCLX - Gross Profit Margin|Gross Margin TVGN (Tevogen Bio Holdings Inc.)|Gross Profit Rate ACOG|Cognition Therapeutics Inc. - Gross Margin|IKT - Gross Margin|SAVA: Gross Margin|Assertio Holdings, Inc. - Gross Profit Rate|COYA (Coya) - Gross Margin|Gross Return on Sales VTGN (Vistagen Therapeutics)|Gross Profitability Ovid Rx (OVID)|Acumen Pharmaceuticals - Gross Return on Sales|Gross Profitability CervoMed, Inc. CRVO|Gross Margin Alterity Therapeutics ATHE|CLNN: Return on Gross Profit|PEPG (pepgen.com) - Gross Return on Sales|Jupiter Neurosciences Inc (JUNS) - Gross Profitability|Relmada Therapeutics - Gross Profit Rate|ANVS (Annovis Bio Inc) - Gross Margin|GRCE: Gross Profit Rate|Gross Profitability Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Gross Profit Rate|Gross Profitability neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Gross Profit Margin|MTVA: Return on Gross Profit|NeurAxis, Inc (NRXS) - Return on Gross Profit|HSDT: Gross Margin|PASG - Return on Sales by Gross Profit|Gross Profitability Neuphoria Therapeutics, Inc.|Gross Profitability NERV|Gross Margin ATHA|ADXN (Addex Therapeutics Ltd) - Gross Profit Rate|Gross Profitability alzamend.com ALZN|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)